The simplest way to read late-August COVID in the United States is to start with the upstream signal. CDC’s wastewater network shows national viral activity at moderate levels, with method updates implemented on August 15 to keep the metric stable as reporting changes. That combination—rising activity off a low summer base, plus a refreshed method—explains why local curves feel jumpier than they did in early summer.
Hospital data follow more slowly, but they are moving. Forecasts point to roughly nine thousand new COVID hospital admissions nationally in the coming week, an uptick from about 8,400 admissions for the week ending August 23. These are not winter-surge numbers, yet they confirm a real increase.
On the ground, emergency-department patterns are uneven. Nationally, overall acute respiratory illness remains very low, while COVID activity is increasing in many areas. That means most EDs are not seeing wall-to-wall respiratory cases, but COVID’s share within that low baseline is growing. Recent aggregates put the hospitalization rate at about 1.7 per 100,000—roughly double two months prior—and test positivity near 11 percent for the week ending August 23.
Variants explain part of the speed. Through mid-August, the NB.1.8.1 “Nimbus” strain held a large share of infections. In late August, the XFG “Stratus” variant accelerated in multiple regions, becoming dominant nationally. As with prior Omicron waves, the clinical picture is familiar: upper-airway symptoms, significant sore throat reports, and short incubation windows. The global health community has not flagged increased severity, and nothing in current U.S. signals contradicts that.
The vaccine timetable resets this fall. U.S. regulators have advised that the 2025–26 vaccines be monovalent JN.1-lineage, preferably LP.8.1, aligning formulation with what has been circulating and projected. Policy choices ahead include whether to keep broad recommendations or to target more narrowly by risk, with access and messaging shaped by whatever approach is adopted.
Treatment remains straightforward in principle and complicated in practice. Nirmatrelvir/ritonavir (Paxlovid) and molnupiravir are still the outpatient oral antivirals, but eligibility, timing, and cost constraints shape real-world use. The therapeutic window is within five days of symptom onset. List pricing for Paxlovid is high; insurance coverage and assistance programs determine the out-of-pocket picture for many patients.
What this adds up to: a late-summer rise that shows up first in wastewater and forecasts, then in admissions. Not a system-breaking surge, but enough to stress clinics that already run lean. The signal is credible, the trend is real, and the fall vaccine formula is set. From here, the data worth watching are simple—wastewater levels, admissions, and the speed of the Stratus handoff—and they will tell us whether this is a shallow wave or the front edge of autumn.